256 related articles for article (PubMed ID: 17510427)
1. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics.
Hartford C; Vasquez E; Schwab M; Edick MJ; Rehg JE; Grosveld G; Pui CH; Evans WE; Relling MV
Cancer Res; 2007 May; 67(10):4965-72. PubMed ID: 17510427
[TBL] [Abstract][Full Text] [Related]
2. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
3. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Biochem Biophys Res Commun; 2013 Jul; 437(2):280-6. PubMed ID: 23811272
[TBL] [Abstract][Full Text] [Related]
4. Establishment of thiopurine S-methyltransferase gene knockdown in jurkat T-lymphocytes: an in vitro model of TPMT polymorphism.
Misdaq M; Andag R; Oellerich M; Asif AR; von Ahsen N
Ther Drug Monit; 2012 Oct; 34(5):584-92. PubMed ID: 22972540
[TBL] [Abstract][Full Text] [Related]
5. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
Yates CR; Krynetski EY; Loennechen T; Fessing MY; Tai HL; Pui CH; Relling MV; Evans WE
Ann Intern Med; 1997 Apr; 126(8):608-14. PubMed ID: 9103127
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
Coulthard SA; Matheson EC; Hall AG; Hogarth LA
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M
Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
11. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Lennard L; Lilleyman JS
Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
[TBL] [Abstract][Full Text] [Related]
12. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression.
Hogarth LA; Redfern CP; Teodoridis JM; Hall AG; Anderson H; Case MC; Coulthard SA
Biochem Pharmacol; 2008 Oct; 76(8):1024-35. PubMed ID: 18708030
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity.
Liu C; Janke LJ; Yang JJ; Evans WE; Schuetz JD; Relling MV
Cancer Chemother Pharmacol; 2017 Aug; 80(2):287-293. PubMed ID: 28623449
[TBL] [Abstract][Full Text] [Related]
14. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
Krynetski EY; Krynetskaia NF; Yanishevski Y; Evans WE
Mol Pharmacol; 1995 Jun; 47(6):1141-7. PubMed ID: 7603453
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
16. Implementation of TPMT testing.
Lennard L
Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology and pharmacogenetics of thiopurines.
Sahasranaman S; Howard D; Roy S
Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three methods for measuring thiopurine methyltransferase activity in red blood cells and human leukemia cells.
Karim H; Appell ML; Fotoohi A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():80-5. PubMed ID: 24113235
[TBL] [Abstract][Full Text] [Related]
19. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]